Skip to main content

EASD 2018 Annual Meeting coverage

Conference highlights

10-10-2018 | Laparascopic gastric band | EASD 2018 | News

Gastric banding has little effect on beta-cell decline in early type 2 diabetes

The results of the adult surgery study from the RISE consortium show that gastric banding has only a small effect on the deterioration of beta-cell function relative to metformin, despite causing markedly greater weight loss.

10-09-2018 | Diabetes prevention | EASD 2018 | News

Mixed results from the diabetes prevention PREVIEW project

The PREVIEW project investigators have reported broadly positive results, but tempered by issues such as a high dropout rate.

10-05-2018 | Hyperglycemia | EASD 2018 | News

ADA/EASD consensus report on managing hyperglycemia in type 2 diabetes published

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

10-04-2018 | Empagliflozin | EASD 2018 | News

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

10-04-2018 | GLP-1 agonists | EASD 2018 | News

Promising phase II data for dual GIP and GLP-1 receptor agonist

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

10-03-2018 | Lixisenatide | EASD 2018 | News

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

The ADA/EASD hyperglycemia guidelines

10-04-2018 | Hyperglycemia | Video | Article

What’s new in the 2018 ADA/EASD hyperglycemia management consensus report

Hyperglycemia management in type 2 diabetes guidelines author Melanie Davies discusses the key updates in the 2018 edition, the evidence behind them, and the experience of being part of a trans-Atlantic consensus group (5:13).

10-05-2018 | Hyperglycemia | EASD 2018 | Article

A Canadian nurse’s view of the ADA/EASD guidelines

Nurse consultant and diabetes educator Lori Berard discusses the consensus report on managing hyperglycemia in people with type 2 diabetes (2:42).

10-04-2018 | Hyperglycemia | EASD 2018 | Article

The ADA/EASD consensus report: A view from primary care

Amrit Lamba gives his view of what the updated ADA/EASD hyperglycemia guidelines mean for primary care practitioners (6:08).

20 years of the UKPDS

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

09-30-2018 | UKPDS | At a glance | Article

What we learned from the UKPDS

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

10-03-2018 | UKPDS | EASD 2018 | Article

The far reaching effects of the UKPDS

Professor Miles Fisher talks about the how the UKPDS shook up the treatment landscape for people with diabetes and set the stage for modern clinical research (3:13).

Expert interviews

More research

10-12-2018 | Type 2 diabetes | EASD 2018 | News

Predictors of rapid type 2 diabetes progression revealed

Researchers have used data from the UK Biobank to uncover predictors of rapid progression to insulin dependence, including pulse rate and maternal diabetes.

10-12-2018 | Prognosis | EASD 2018 | News

Simple clinical measures may be better prognosticators than proposed diabetes subgroups

The recently proposed five diabetes subgroups are reproducible, but are more complicated and no better than simple clinical variables for predicting disease progression and treatment response, researchers have reported.

10-11-2018 | Glycemic control | EASD 2018 | News

Natural HbA1c variability can obscure treatment effects

A single glycated hemoglobin measurement will not be sufficient to gauge treatment effects or the need for intensification in many type 2 diabetes patients, research shows.

Image Credits